HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) (“IMPAX” or “the Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Applications (ANDA) for Nadolol/Bendroflumethiazide 40mg/5mg and 80mg/5mg, generic of Corzide®. The Company will begin marketing the products through its Global Pharmaceuticals division in the near future.
